HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MRS 1191

a selective A3 adenosine receptor antagonist; structure given in first source

Also Known As:

MRS-1191

Networked: 6 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Dihydropyridines: 214
      - MRS 1191: 6

Experts

1.	Joo, Jin Deok: 2 articles (01/2019 - 10/2006)
2.	Choi, Jin Woo: 1 article (01/2019)
3.	In, Jang Hyeok: 1 article (01/2019)
4.	Jung, Hong Soo: 1 article (01/2019)
5.	Kim, Jin A: 1 article (01/2019)
6.	Kim, Yong Shin: 1 article (01/2019)
7.	Kim, Yumi: 1 article (01/2019)
8.	Kwon, So Young: 1 article (01/2019)
9.	Park, Yoo Jung: 1 article (01/2019)
10.	Chen, Yu: 1 article (02/2011)

Related Diseases

1.	Sepsis (Septicemia) 02/01/2011 - "Using a mouse model of cecal ligation and puncture (CLP)-induced sepsis, we found that MRS-1191 reduces acute lung injury and PMN accumulation in lung tissue. " 10/01/2006 - "A3AR WT mice treated with N6-(3-iodobenzyl)ADO-5'N-methyluronamide (IB-MECA; a selective A3AR agonist) or 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-(+/-)-dihydropyridine-3,5-dicarboxylate (MRS-1191; a selective A3AR antagonist) had improved or worsened 7-day survival after induction of sepsis, respectively. "
2.	Ischemia 02/01/2001 - "GR-69019X (A(1)/A(3)) and MRS-1191/MRS-1220 (A(3)) significantly increased infarct size in APC hearts when administered before ischemia and significantly decreased functional recovery when administered during both ischemia and reperfusion (P < 0.05 vs. APC). " 11/01/2004 - "Animals were treated with the selective A3 receptor agonist IB-MECA (300 microg/kg intravenously) given 15 min before ischemia or with IB-MECA as described, with pretreatment 15 min earlier with the selective A3AR antagonist MRS-1191, the nonsulfonylurea adenosine triphosphate-sensitive potassium channel-blocking agent U-37883A, or the nitric oxide synthase inhibitor N-nitro-l-arginine benzyl ester. "
3.	Acute Lung Injury 02/01/2011 - "Using a mouse model of cecal ligation and puncture (CLP)-induced sepsis, we found that MRS-1191 reduces acute lung injury and PMN accumulation in lung tissue. "
4.	Seizures (Absence Seizure) 05/01/2004 - "Application of ZM 241385, an adenosine A(2A) receptor antagonist, shortened the duration of epileptiform activity, whereas administration of MRS 1191, an adenosine A(3) receptor antagonist, both decreased the duration and intensity of seizures. "
5.	Infarction (Infarctions) 02/01/2001 - "GR-69019X (A(1)/A(3)) and MRS-1191/MRS-1220 (A(3)) significantly increased infarct size in APC hearts when administered before ischemia and significantly decreased functional recovery when administered during both ischemia and reperfusion (P < 0.05 vs. APC). "

Related Drugs and Biologics

1.	N(6)- (3- iodobenzyl)- 5'- N- methylcarboxamidoadenosine
2.	1,4-dihydropyridine (dihydropyridine)
3.	Adenosine A2A Receptor (Adenosine A2A Receptors)
4.	Nitric Oxide Synthase (NO Synthase)
5.	Cytokines
6.	Potassium Channels (Potassium Channel)
7.	Proteins (Proteins, Gene)
8.	Esters
9.	Arginine (L-Arginine)
10.	Amitriptyline (Elavil)

Related Therapies and Procedures

1.	Punctures
2.	Ligation